Recent updates and developments in PET imaging of prostate cancer

Steven P. Rowe; Geoffrey B. Johnson; Martin G. Pomper; Michael A. Gorin; Spencer C. Behr

doi:10.1007/s00261-020-02570-y

Recent updates and developments in PET imaging of prostate cancer

Steven P. Rowe, Geoffrey B. Johnson, Martin G. Pomper, Michael A. Gorin, Spencer C. Behr

Radiology

Research output: Contribution to journal › Article › peer-review

Abstract

A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na¹⁸F as well as more tumor-specific compounds such as ¹¹C-choline and ¹⁸F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).

Original language	English (US)
Pages (from-to)	4063-4072
Number of pages	10
Journal	Abdominal Radiology
Volume	45
Issue number	12
DOIs	https://doi.org/10.1007/s00261-020-02570-y
State	Published - Dec 2020

Keywords

Axumin
Bombesin
Choline
Fluciclovine
GRPR
PSMA

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging
Gastroenterology
Urology

Access to Document

10.1007/s00261-020-02570-y

Cite this

@article{6d2f86217b334d7c980db25df825a04c,

title = "Recent updates and developments in PET imaging of prostate cancer",

abstract = "A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).",

keywords = "Axumin, Bombesin, Choline, Fluciclovine, GRPR, PSMA",

author = "Rowe, {Steven P.} and Johnson, {Geoffrey B.} and Pomper, {Martin G.} and Gorin, {Michael A.} and Behr, {Spencer C.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = dec,

doi = "10.1007/s00261-020-02570-y",

language = "English (US)",

volume = "45",

pages = "4063--4072",

journal = "Abdominal Radiology",

issn = "2366-004X",

publisher = "Springer New York",

number = "12",

}

TY - JOUR

T1 - Recent updates and developments in PET imaging of prostate cancer

AU - Rowe, Steven P.

AU - Johnson, Geoffrey B.

AU - Pomper, Martin G.

AU - Gorin, Michael A.

AU - Behr, Spencer C.

PY - 2020/12

Y1 - 2020/12

N2 - A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).

AB - A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).

KW - Axumin

KW - Bombesin

KW - Choline

KW - Fluciclovine

KW - GRPR

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85084813611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084813611&partnerID=8YFLogxK

U2 - 10.1007/s00261-020-02570-y

DO - 10.1007/s00261-020-02570-y

M3 - Article

C2 - 32417934

AN - SCOPUS:85084813611

SN - 2366-004X

VL - 45

SP - 4063

EP - 4072

JO - Abdominal Radiology

JF - Abdominal Radiology

IS - 12

ER -

Recent updates and developments in PET imaging of prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this